Chemotherapeutic selectivity conferred by selenium: A role for p53-dependent DNA repair

Molecular Cancer Therapeutics

Volumn 6, Issue 1, 2007, Pages 355-361

  Fischer, Joshua L ^a,c   Mihelc, Elaine M ^a,c   Pollok, Karen E ^b   Smith, Martin L ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WALTHER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DNA; OXALIPLATIN; PROTEIN P53; SELENIUM; SELENOMETHIONINE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG SELECTIVITY; EMBRYO; FIBROBLAST; GENE MUTATION; INTESTINE EPITHELIUM; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIATION EXPOSURE; ULTRAVIOLET RADIATION; WILD TYPE;

ANIMALS; CELL SURVIVAL; DNA; DNA REPAIR; FIBROBLASTS; GENOME; HUMANS; MICE; ORGAN SPECIFICITY; ORGANOPLATINUM COMPOUNDS; ORGANOSELENIUM COMPOUNDS; SELENOMETHIONINE; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS;

EID: 33846828457     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0472     Document Type: Article

References (34)

1. Meuillet E, Stratton S, Prasad Cherukuri D, et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 2004;91:443-58.
2. Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10: 2561-9.
3. Fakih MG, Pendyala L, Smith PF, et al. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors. Clin Cancer Res 2006;12:1237-44.
4. Reid ME, Stratton MS, Lillico AJ, et al. A report of high-dose selenium supplementation: response and toxicities. J Trace Elem Med Biol 2004;18: 69-74.
5. Fakih MG, Pendyala L, Creaven PJ, Smith P, Ross ME, Rustum Y. A Phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (CPT-11) in patients with advanced solid tumors. Proc Am Assoc Cancer Res 2006;47:686.
6. Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997;56:331-41.
7. Siej K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 2004; 93:320-7.
8. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998;24:331-44.
9. Li Q, Yu JJ, Mu C, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000;20:645-52.
10. Ford JM, Hanawalt PC. Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. Proc Natl Acad Sci U S A 1995;92:8876-80.
11. Ford JM, Hanawalt PC. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J Biol Chem 1997;272:28073-80.
12. Ford JM, Baron EL, Hanawalt PC. Human fibroblasts expressing the human papillomavirus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res 1998;58: 599-603.
13. Bowman KK, Sicard DM, Ford JM, Hanawalt PC. Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed human cells. Mol Carcinog 2000;29:17-24.
14. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci U S A 1999;96:424-8.
15. Wakasugi M, Kawashima A, Morioka H, et al. DDB accumulates at DNA damage sites immediately after UV irradiation and directly stimulates nucleotide excision repair. J Biol Chem 2002;277:1637-40.
16. Fitch ME, Cross IV, Ford JM. p53 responsive nucleciticle excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo, Carcinogenesis 2003;24: 843-50.
17. Fitch ME, Cross IV, Turner SJ, et al. The DDB2 nucleotide excision repair gene product p48 enhances global genomic repair in p53 deficient human fibroblasts. DNA Repair (Amst) 2003;2:819-26.
18. Adimoolam S, Ford JM. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci U S A 2002;99:12985-90.
19. Chen Z, Xu XS, Yang J, Wang G. Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis. Carcinogenesis 2003;24:1111-21.
20. You JS, Wang M, Lee SH. Biochemical analysis of the damage recognition process in nucleotide excision repair. J Biol Chem 2003;278: 7476-85.
21. Seo YR, Sweeney C, Smith ML. Selenomethionine induction of DNA repair response in human fibroblasts. Oncogene 2002;21:3663-9.
22. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 2002;99: 14548-53.
23. Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev 1997;11:558-70.
24. Seemann S, Hainaut P. Roles of thioredoxin reductase 1 and APE/ Ref-1 in the control of basal p53 stability and activity. Oncogene 2005;24: 3853-63.
25. Goel A, Fuerst F, Hotchkiss E, Boland CR. Selenomethionine induces p53 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cancer Biol Ther 2006;5:529-35.
26. Chung HJ, Yoon SI, Shin SH, et al. p53-mediated enhancement of radiosensitivity by selenophosphate synthetase 1 overexpression. J Cell Physiol 2006;209:131-41.
27. Smith ML, Lancia JK, Mercer TI, Ip C. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res 2004;24: 1401-8.
28. Smith ML, Ford JM, Hollander MC, et al. P53-mediated DNA repair responses to UV-radiation: studies of mouse cells lacking p53, p21 and/ or Gadd45a genes. Mol Cell Biol 2000;20:3705-14.
29. Fischer JL, Cao S, Durrani FA, Fakih M, Rustum YM, Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Proc Am Assoc Cancer Res 2006;47:127.
30. Kim MS, Li SL, Bertolami CN, Cherrick HM, Park NH. State of p53, Rb and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res 1993;13:1405-13.
31. 1 arrest and suppression of the malignant phenotype by wild-type p53 in human squamous cell carcinoma cells. Exp Cell Res 1997;233: 135-44.
32. Smith ML, Chen IT, Zhan Q, O'Connor PM, Fornace AJ, Jr. Involvement of the p53 tumor suppressor gene in repair of UV-type DNA damage. Oncogene 1995;10:1053-9.
33. Sieja K. Selenium (Se) deficiency in women with ovarian cancer undergoing chemotherapy and the influence of supplementation with this micro-element on biochemical parameters. Pharmazie 1998;53:473-6.
34. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.